https://www.live-feeds.com/feed/early-data-indicates-an-a-i-generated-drug-could-slow-agingContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/early-data-indicates-an-a-i-generated-drug-could-slow-aginghttps://www.live-feeds.com/feed/early-data-indicates-an-a-i-generated-drug-could-slow-aging#u67942Mon, 14 Sep 2026 16:20:25 +0000Recent developments in predictive biology and drug delivery show new paths for treating degenerative conditions. Astromech is creating AI models that leverage evolutionary history to predict biological risks and regulatory mechanisms. Separately, a University of Alberta neuroscientist found that biodegradable nanoparticles can reduce brain plaque proteins and improve memory in mice with Alzheimer's disease. These advancements build on a broader trend of using artificial intelligence and specialized delivery systems to automate drug development and refine patient screening for clinical tri https://www.live-feeds.com/feed/early-data-indicates-an-a-i-generated-drug-could-slow-aginghttps://www.live-feeds.com/feed/early-data-indicates-an-a-i-generated-drug-could-slow-aging#u63948Thu, 10 Sep 2026 12:49:19 +0000A newly developed blood-based screening algorithm has successfully reduced the volume of unnecessary PET scans required to enroll patients at risk of Alzheimer disease into clinical trials. Scientists at the Keck School of Medicine of USC published these findings in the journal Alzheimer's & Dementia. Meanwhile, researchers continue exploring artificial intelligence applications across healthcare, including blood glucose prediction models and automated drug development. These technological pushes arrive as patients increasingly turn to alternative therapies like injected peptides to m https://www.live-feeds.com/feed/early-data-indicates-an-a-i-generated-drug-could-slow-aginghttps://www.live-feeds.com/feed/early-data-indicates-an-a-i-generated-drug-could-slow-aging#u61950Tue, 08 Sep 2026 22:43:22 +0000Insilico Medicine's AI-developed drug rentosertib may slow aging by reducing biological age markers in patients. Originally designed to treat idiopathic pulmonary fibrosis, a disease causing progressive lung scarring, the drug demonstrated anti-aging signals in a small patient group. These results, published in Nature Biotechnology, utilized proteomic aging clocks to measure the drug's geroprotective effects. While initially targeted at chronic lung disease and lifespan extension, the early data suggests the drug can reverse specific markers of biological age.Why it mattersAI drug di